- Home
- RFL vs LENZ Comparison
RFL vs LENZ Comparison
Compare RFL & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFL | LENZ |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.1M | 155.5M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RFL | LENZ |
|---|---|---|
| Price | $2.45 | $5.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.00 |
| AVG Volume (30 Days) | 105.7K | ★ 709.5K |
| Earning Date | 06-10-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $917,000.00 | ★ $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | N/A | $197.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $4.54 |
| 52 Week High | $3.96 | $50.19 |
Technical Indicators
Market Signals| Indicator | RFL | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 61.43 | 50.46 |
| Support Level | $1.21 | $4.59 |
| Resistance Level | $3.96 | $6.18 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 64.83 | 72.08 |
Price Performance
Historical ComparisonAbout RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.